Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients

Overview

To explore biomarkers predictive of clinical response to sorafenib in unresectable hepatocellular carcinoma using the Prometheus Platform To analyze expression and activation status of receptor tyrosine kinases in signal transduction pathways in FNA samples and circulating tumor cells. To identify negative predictive markers to sorafenib. To elucidate signal transduction pathway attributable to sorafenib resistance. To monitor changes in the RTK activation status during sorafenib treatment using circulating tumor cells. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to sorafenib.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: January 13, 2014

Arms, Groups and Cohorts

  • Hepatocellular carcinoma patients treated with sorafenib

Clinical Trial Outcome Measures

Primary Measures

  • Biomarkers predictive
    • Time Frame: 36months
    • To explore biomarkers predictive of clinical response to sorafenib in unresectable hepatocellular carcinoma using the Prometheus Platform A. To analyze expression and activation status of receptor tyrosine kinases in signal transduction pathways in FNA samples and circulating tumor cells B. To identify negative predictive markers to sorafenib

Secondary Measures

  • Signal transduction pathway
    • Time Frame: 36months
    • To elucidate signal transduction pathway attributable to sorafenib resistance.
  • The RTK activation status.
    • Time Frame: 36months
    • To monitor changes in the RTK activation status during sorafenib treatment using circulating tumor cells.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with histologically confirmed hepatocellular carcinoma (HCC) or a combination of radiologically compatible finding to HCC, alpha-fetoprotein > 400ng/mL and liver cirrhosis – Inoperable disease as defined by (Localized disease in a portion of the liver that doses not allow the possibility of complete surgical removal of the tumor with a clear resection margin OR Presence of extra-hepatic disease OR Main portal vein or hepatic vein involvement (invasion or tumor thrombus) OR The HCC must not be amenable to intra-arterial therapy or local ablative therapy) – Minimum life expectancy of 12 weeks – Age > 18 years. – ECOG Performance Status of ≤ 2 – Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening: (Hemoglobin > 9.0 g/dl,Absolute neutrophil count>1,500/mm3, Platelet count>75,000/μl,Total bilirubin < 1.5 times the upper limit of normal,ALT and AST < 5 x upper limit of normal,Albumin ≥ 3g/dL,PT-INR/PTT < 1.5 x upper limit of normal,Serum creatinine < 1.5 x upper limit of normal or Creatinine clearance ≥ 50mL/min) – Signed and dated informed consent before the start of specific protocol procedures. – FNA will be performed in patients with feasible biopsy site Exclusion Criteria:

  • Decompensated cirrhosis or stage C (Index > 10) according to the Child-Pugh Classification – Other concomitant anticancer agent, including Tamoxifen and Interferon – Active clinically serious infections (> grade 2 CTCAE version 3.0) – History of organ allograft – Patients with evidence or history of bleeding diasthesis – Patients undergoing renal dialysis – Radiotherapy during study or within 4 weeks of start of study drug. – Prior exposure to the study drug. – Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Samsung Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ho Yeong Lim, Professor of Medicine, Sungkyunkwan University School of Medicine, Department of Hematology and Oncology – Samsung Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.